Clinical trials: Brain Diseases, Metabolic
Phenylketonuria
Phenylalanine and Its Impact on Cognition
The PICO-Study is a randomized, placebo-controlled, crossover, non-inferiority trial conducted to add evidence to the current European treatment guidelines for adult patients with phenylketonuria.
- Trial name
- PICO (NCT03788343)
- Testing
- Phenylalanine
- Where
- Switzerland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Probable Alzheimer Disease, Parkinson Disease
In Vivo Alzheimer Proteomics
In France, an estimated 860 000 patients are affected by Alzheimer Disease (AD) which represents, as in other developed countries, a major public health issue.
- Conditions
- Probable Alzheimer Disease, Parkinson Disease, Neurological Disease Without Cognitive Degradation, Brain Trauma
- Trial name
- PROMARA (NCT02263235)
- Testing
- administration of stable isotope-labelled leucine-, collection of CSF, blood, urine, saliva
- Where
- France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Montpellier
Niemann-Pick Type C Disease
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
- Trial name
- NCT07082725
- Testing
- Nizubaglustat
- Where
- 34 sites in United States, Argentina and 13 more
- Volunteers
- 72 people
- Sponsor
- Azafaros B.V.
Wilson Disease
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.
- Trial name
- NCT02763215
- Testing
- Standard of Care Medications
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 64 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Alzheimer Disease, Dementia
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease
The goal of this double-blinded placebo-controlled randomized trial is to determine the optimal dose of nicotinamide riboside (NR), in individuals with Alzheimer's disease (AD).
- Trial name
- NCT05617508
- Testing
- Nicotinamide Riboside supplementation 1000mg daily in total, Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)
- Where
- 2 sites in Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Hepatic Encephalopathy
A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
The aim of the current study is to determine whether rifaximin or lactulose is more effective in preventing the development of severe hepatic encephalopathy in hospitalized patients with cirrhosis and new onset kidney failure.
- Trial name
- NCT02086825
- Testing
- Rifaximin, Lactulose
- Where
- United States
- Sponsor
- NYU Langone Health
Wilson Disease
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
The goal of this clinical trial is to learn if GC310 (AAV5-ATP7B) gene therapy can treat Wilson's Disease (WD) in patients over the age of 18 years old.
- Trial name
- NCT07173933
- Testing
- GC310
- Where
- China
- Volunteers
- 15 people
- Sponsor
- GeneCradle Inc
Phenylketonuria (PKU)
Simple Breath Test to Examine Phenylalanine Metabolism
Phenylketonuria(PKU)is a rare condition caused by the body's inability to properly breakdown an amino acid called phenylalanine(PHE), due to a missing enzyme, phenylalanine hydroxylase(PAH).
- Trial name
- NCT02009904
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Liver Cirrhosis, Hepatoencephalopathy, Early Fatal Progressive
Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy
Patients with cirrhosis are particularly prone to infection which is frequently a precipitant of hepatic encephalopathy, renal failure and circulatory collapse.
- Trial name
- RIFSYS (NCT02019784)
- Testing
- Rifaximin-α
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- King's College Hospital NHS Trust
Frontotemporal Dementia
Safety Study of Intranasal Oxytocin in Frontotemporal Dementia
Oxytocin is a hormone produced by the brain that appears to have important roles in social cognition and emotion in humans. In a pilot study, the effects of a single dose of oxytocin on measures of emotion recognition and…
- Trial name
- FTDOXY10EF (NCT01386333)
- Testing
- oxytocin, Saline Nasal Mist
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diabetes, Gestational, Glucose Metabolism Disorders
Gestational Diabetes Mellitus and Neurodevelopment in Newborns
The purpose of this study is to evaluate the feasibility of using a quantitative EEG method to evaluate neurodevelopment in newborns and to evaluate whether subtle neurodevelopmental deficits can be detected in newborns from…
- Trial name
- NCT02779452
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Friedreich Ataxia
Characterization of the Interruptions of the GAA Expansion and Study of Their Influence on the Severity of Friedreich's Ataxia
Friedreich's ataxia (FA) is the most frequent recessive genetic ataxia with an estimated prevalence of 1/50 000. The first symptoms appear around the age of 10 years with a progressive course and the need for an armchair 10- 15…
- Trial name
- INTREP-AF (NCT04346238)
- Testing
- Reuse of existing data from patients' medical records
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Montpellier
Portal Hypertension, Hepatic Encephalopathy
The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy
Through a multicenter randomized controlled trial of TIPS to prevent post-hepatitis B cirrhosis of esophagogastric varices, the incidence of hepatic encephalopathy, the rate of stent patency, the incidence of rebleeding and…
- Trial name
- NCT03825848
- Testing
- trans jugular intrahepatic portal systemic shunt
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Shanghai Zhongshan Hospital
Alzheimer's Disease, Mild Cognitive Impairment
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved…
- Trial name
- NCT01099332
- Testing
- Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adeona Pharmaceuticals
Type I Gaucher Disease
Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.
- Trial name
- NCT01463215
- Testing
- Ambroxol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Exsar Corporation
Overweight and Obesity
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
The purpose of this study is to determine how different behavioral interventions designed to alter food perceptions and behaviors affect brain responses to food, eating behaviors, and body weight.
- Trial name
- NCT05107908
- Testing
- Active Implicit Priming, Control Implicit Priming, Food Exposure Task
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Mellitus, Non-Proliferative Diabetic Retinopathy
Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus
In Type 2 Diabetes mellitus patients we will: 1. quantify vasculopathy and blood-retinal barrier (BRB) leakage 2. measure blood-brain barrier (BBB) permeability and neuroanatomical changes 3.
- Conditions
- Type 2 Diabetes Mellitus, Non-Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT01107132
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Soroka University Medical Center
Alzheimer's Disease
ADNI: Alzheimer's Disease Neuroimaging Initiative
The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD).
- Trial name
- NCT00106899
- Testing
- Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
- Where
- 59 sites in United States, Canada
- Volunteers
- 818 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Diabetes, Diabetic Ketoacidosis
Evaluation of a Non-invasive Brain Compliance Measurement Device
This is a research study to understand how diabetic ketoacidosis may affect the brain and learning and to see if these changes are transient or permanent.
- Trial name
- NCT01753921
- Testing
- this is not an intervention study, MRI
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Stanford University
Phenylketonurias
A Prospective Clinical Study of Phenylketonuria (PKU)
This is a study for adults and children ≥ 14 years old who have Phenylketonuria (PKU) with uncontrolled plasma Phe levels. No clinical intervention or study drug is provided by BioMarin in this study.
- Trial name
- NCT04452513
- Where
- 14 sites in United States
- Volunteers
- 32 people
- Sponsor
- BioMarin Pharmaceutical